EBGLYSS is an FDA-approved drug for treating moderate-to-severe eczema by targeting IL-13, offering relief to patients ...

The Food and Drug Administration had recently approved a new drug for the treatment of atopic dermatitis (eczema), which can ...

Atopic dermatitis, or eczema ... Among the common side effects of EBGLYSS were eye and eyelid inflammation, including redness, swelling and itching. Some also experience injection site reactions ...

for the treatment of adults and children age 12 years and older who have moderate-to-severe atopic dermatitis (AD) that is not well controlled, despite treatment with topical prescription therapies.

Ebglyss is a new biologic treatment for moderate-to-severe eczema that isn’t controlled with topical therapies. The ...

Adbry ® (tralokinumab-ldrm) 300 mg/2 mL single-dose autoinjector in the United States. Adbry is currently indicated in the U.S. for patients 12 years and older with moderate-to-severe atopic ...

Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype Following recent ...

The FDA has approved Ebglyss (lebrikizumab-lbkz), a new biologic treatment for moderate-to-severe atopic dermatitis in people ...

"Patients still struggle to control their moderate-to-severe atopic dermatitis with currently ... adverse events in the trials included eye and eyelid inflammation, injection site reactions ...